9 Meters Biopharma Announces Agreement with the European Biomedical Research Institute of Salerno (EBRIS) to Continue Evaluation of Larazotide for COVID-19 Respiratory Complications

9 Meters Biopharma, Inc. (NASDAQ: NMTR) announces agreement with the European Biomedical Research Institute of Salerno (EBRIS) to continue evaluation of larazotide for COVID-19 respiratory complications

Intuitive Venture PartnersDecember 21, 20209 Meters, 2020

9 Meters Biopharma, Inc. Announces Closing of Offering of Common Stock

9 Meters Biopharma, Inc. (NASDAQ: NMTR) announces closing of offering of common stock

Intuitive Venture PartnersDecember 15, 20209 Meters, 2020

9 Meters Biopharma, Inc. Announces Proposed Public Offering of Common Stock

9 Meters Biopharma, Inc. (NASDAQ: NMTR) announces proposed public offering of common stock

Intuitive Venture PartnersDecember 10, 20209 Meters, 2020

Entera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announces FDA approval of IND application for EB613 – an oral human parathyroid hormone (1-34) for the treatment of osteoporosis

Intuitive Venture PartnersDecember 10, 2020entera bio, 2020

Entera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announces completion of enrollment in phase 2 clinical trial of Eb613 In osteoporosis

Intuitive Venture PartnersNovember 9, 2020entera bio, 2020